{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Apolo AB"],"funding":["Intramural NIH HHS","NCI NIH HHS"],"pagination":["63-71"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9750497"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["177"],"pubmed_abstract":["<h4>Background</h4>The phase III CheckMate 9ER trial originally included a nivolumab plus ipilimumab plus cabozantinib triplet arm, which was discontinued early due to the evolving treatment landscape for first-line advanced renal cell carcinoma (aRCC). We report an exploratory analysis of patients randomised to the triplet regimen before enrolment discontinuation.<h4>Methods</h4>Patients with clear-cell aRCC received nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) Q3W for four cycles with once-daily cabozantinib (40 mg), then nivolumab (240 mg) Q2W plus once-daily cabozantinib (40 mg). CheckMate 9ER primary (progression-free survival [PFS] by blinded independent central review [BICR]) and key secondary (overall survival [OS], objective response rate [ORR] by BICR, and safety) endpoints were"],"journal":["European journal of cancer (Oxford, England : 1990)"],"pubmed_title":["Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial."],"pmcid":["PMC9750497"],"funding_grant_id":["ZIA BC011594","ZIA BC011351","P50 CA101942","P30 CA008748","P30 CA006516"],"pubmed_authors":["Simsek B","Scheffold C","Powles T","Zhang J","Escudier B","Apolo AB","Burotto M","Motzer RJ","Choueiri TK"],"additional_accession":[]},"is_claimable":false,"name":"Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial.","description":"<h4>Background</h4>The phase III CheckMate 9ER trial originally included a nivolumab plus ipilimumab plus cabozantinib triplet arm, which was discontinued early due to the evolving treatment landscape for first-line advanced renal cell carcinoma (aRCC). We report an exploratory analysis of patients randomised to the triplet regimen before enrolment discontinuation.<h4>Methods</h4>Patients with clear-cell aRCC received nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) Q3W for four cycles with once-daily cabozantinib (40 mg), then nivolumab (240 mg) Q2W plus once-daily cabozantinib (40 mg). CheckMate 9ER primary (progression-free survival [PFS] by blinded independent central review [BICR]) and key secondary (overall survival [OS], objective response rate [ORR] by BICR, and safety) endpoints were","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-05-28T02:15:10.541Z","creation":"2025-04-04T09:39:47.479Z"},"accession":"S-EPMC9750497","cross_references":{"pubmed":["36327527"],"doi":["10.1016/j.ejca.2022.09.020"]}}